Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners

Ann Livingstone (), Donna Milne, Kathy Dempsey, Danielle Marie Muscat, Alexander M. Menzies, Kirsten Howard, Martin R. Stockler and Rachael L. Morton
Additional contact information
Ann Livingstone: The University of Sydney
Donna Milne: Peter MacCallum Cancer Centre
Kathy Dempsey: The University of Sydney
Danielle Marie Muscat: The University of Sydney
Alexander M. Menzies: The University of Sydney
Kirsten Howard: The University of Sydney
Martin R. Stockler: The University of Sydney
Rachael L. Morton: The University of Sydney

The Patient: Patient-Centered Outcomes Research, 2021, vol. 14, issue 5, No 16, 635-647

Abstract: Abstract Background Adjuvant immunotherapy is a new treatment paradigm for adults with resected stage 3 melanoma. However, therapy can lead to long-term adverse health impacts, making immunotherapy decisions difficult. This study aimed to explore patients and their partners’ views when considering whether to commence adjuvant immunotherapy. Methods Focus groups and in-depth interviews were conducted among adults with resected stage 3 melanoma and their partners between August 2019 and April 2020. Factors important to adjuvant immunotherapy decision making were explored. Recruitment continued until data saturation, with thematic analysis performed. Results Thirty-six participants were recruited across two cohorts, including 24 patients (mean age 65 years, 71% male), and 12 partners (mean age 69 years, 75% female). Twenty-two patients (92%) received adjuvant immunotherapy, two (8%) declined. Five patients (21%) ceased treatment early because of toxicity. Five themes about adjuvant immunotherapy were common to all participants: (1) life and death; (2) perceived risks and benefits; (3) seeking information; (4) healthcare team relationship; and (5) immunotherapy treatment considerations. Prolonging life was the primary consideration, with secondary concerns about treatment burden, timing, costs and efficacy. Conclusions This information can be used by clinicians to support melanoma treatment decision making.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40271-021-00507-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:14:y:2021:i:5:d:10.1007_s40271-021-00507-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-021-00507-1

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().